Catalog |
name |
Description |
price |
R-R-4194 |
CCR8 antagonist 1 CAS No.723304-76-5 |
CCR8 antagonist 1 (compound 15)/CAS No.723304-76-5 is a potente human CCR8 antagonist with a Ki of 1.6 nM. |
price> |
R-R-4195 |
Vicriviroc maleate CAS No.599179-03-0 |
Vicriviroc maleate (SCH-417690 maleate; SCH-D maleate)/CAS No.599179-03-0 is a potent, selective, oral bioavailable and CNS penetrated antagonist of CCR5, with a Ki of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with IC90s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU 570). |
price> |
R-R-4196 |
CCR1 antagonist 9 CAS No.1220026-26-5 |
CCR1 antagonist 9/CAS No.1220026-26-5 is a potent and selective CCR1 antagonist with an IC50 of 6.8 nM in calcium flux assay. |
price> |
R-R-4197 |
AZD-4818 CAS No.1003566-93-5 |
AZD-4818/CAS No.1003566-93-5 is a potent antagonist of chemokine CCR1. AZD-4818 can be used for researching chronic obstructive pulmonary disease (COPD) . |
price> |
R-R-4198 |
AZD2423 CAS No.1229603-37-5 |
AZD2423/CAS No.1229603-37-5 is a potent, selective, orally bioavailable, and non-competitive CCR2 chemokine receptor negative allosteric modulator. AZD2423 has an IC50 of 1.2 nM for CCR2 Ca2+ flux . |
price> |
R-R-4199 |
CCR4-351 CAS No.2174938-70-4 |
CCR4-351/CAS No.2174938-70-4 is an orally active, potent and selective CCR4 antagonist. CCR4-351, featuring a novel piperidinyl-azetidine motif, has IC50s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4-351 has antitumor activity. |
price> |
R-R-4200 |
AZD-5672 CAS No.780750-65-4 |
AZD-5672/CAS No.780750-65-4 is an orally active, potent, and selective CCR5 antagonist (IC50=0.32 nM). AZD-5672 shows moderate activity against the hERG ion channel (binding IC50=7.3 μM). AZD5672 is a substrate of human P-gp, and inhibits P-gp-mediated digoxin transport (IC50=32 μM). AZD-5672 can be used for the research of rheumatoid arthritis. |
price> |
R-R-4201 |
CCR8 antagonist 2 CAS No.2756350-98-6 |
CCR8 antagonist 2/CAS No.2756350-98-6 is a potent antagonist of CCR8. CCR8 (C-C Motif Chemokine Receptor 8) is predominantly expressed on Treg cells and Th2 cells, but not on Th1 cells. CCR8 antagonist 2 inhibits CCR8 activity, which may be used in the research of diseases mediated by CCR8, such as cancer, and/or neuropathic pain (extracted from patent WO2022000443A1, compound 220). |
price> |
R-R-4202 |
IPG7236 CAS No.2756350-91-9 |
IPG7236/CAS No.2756350-91-9 is a selective CCR8 antagonist. IPG7236 exhibits significant tumor suppression in a mouse xenograft model of human breast cancer. IPG7236 can be used in cancer research. |
price> |
R-R-4203 |
MLN3126 CAS No.628300-71-0 |
MLN3126/CAS No.628300-71-0 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC50 value of 6.3 nM for calcium influx. |
price> |